Request a Quote |
In vitro toxicology

High Content Imaging of 3D Microtissues

Background information

  • The environment created by a 3D culture model allows reconstitution of the natural cellular physiology by promoting the complex cell-cell and cell-matrix network communications found in vivo.
  • For imaging purposes, microtissues are formed using round bottom ultra-low adhesion cell culture plates which promote aggregation of cells into functional 3D microtissues.
  • Microtissues can be formed from single or co-cultured cell populations and their longevity permits use in long-term repeat dose toxicity studies to investigate any cumulative effect.
  • The combination of biologically relevant in vitro 3D cell-based models with multiparametric HCS assays presents a viable screening strategy for the detection of novel therapeutics that cause toxicity early in drug development.


High content imaging of 3D microtissues

Microtissues* HepaRG, liver, spontaneously beating cardiac (mono-and co-cultures available)
Endpoints* GSH content, ROS formation, phospholipidosis, steatosis, mitochondrial membrane potential, ATP content, LDH release
Time Points* 4 hr, 16 hr, 72 hr and 14 day repeat dose

*others available on request


Data from Cyprotex's 3D microtissue high content imaging assays


Get a Quote
Product sheet ADME Guide DDI Guide TOX Guide

Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): +1-888-297-7683
Europe: +44 (0)1625 5051000


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

By clicking on ‘Send’ I agree that my data is being transferred and used by Cyprotex and the affiliated Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our privacy policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below: